Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

Galmed Pharmaceuticals announced a definitive agreement to acquire Colospan Ltd., a medical device company, for $2.5 million in cash and $2.0 million in Galmed shares. The acquisition combines Galmed's public company infrastructure with Colospan's CG-100 intraluminal bypass device, which has FDA Breakthrough Device Designation and is CE marked in Europe. The transaction is expected to close in Q2 2026, with Galmed planning a $6 million investment to launch the device in Europe during H2 2026.